Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMoath AlbliwiANAhmed NabilEAElizabeth M. Azzato

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals TP53 mutations are linked to poor survival in acute myeloid leukemia, implying significant prognostic implications.

Key Points

  • TP53 mutations were associated with lower odds of complete remission in acute myeloid leukemia patients, indicating a worse prognosis.
  • Survival analysis showed a median overall survival of 5.6 months for TP53 mutations compared to 15 months for non-mutated cases.
  • A retrospective analysis utilizing next-generation sequencing and multivariable logistic regression was conducted across 971 AML patients.
  • This study highlights the need for further investigation into the impact of PPM1D mutations on survival, especially with co-occurring TP53 mutations.

Cite This Study

Albliwi et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d669https://doi.org/10.1182/blood-2025-5168
View Full Paper
Ask AI
Bookmark
Share